Humana Inc (HUM)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $54.05B
Last updated: Nov 17, 2026 at 11:06 AM ET
Humana Inc (HUM) Earnings: Report Dates and Results
Humana (HUM) is expected to report earnings on Feb 9, 2027. In the quarter ended Sep 30, 2026, Humana reported EPS of -$0.70, above the -$1.03 estimate. It beat the EPS estimate in 7 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HUM has an expected report date of Feb 9, 2027.
HUM Earnings Call
The latest HUM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, HUM beat 38 and missed 2. Revenue for the quarter ended Sep 30, 2026 was $41.16B, up 26.1% from $32.65B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.70 | -$1.03 | -$1.16 - -$0.60 | +32.04% | Beat | -121.6% | 23 | 0 up, 4 down | Nov 6, 2026 | $41.16B |
| Jun 30, 2026 | $7.61 | $6.22 | $1.61 - $7.94 | +22.35% | Beat | +21.4% | 24 | 5 up, 1 down | Jul 29, 2026 | $40.87B |
| Mar 31, 2026 | $10.31 | $10.20 | $8.08 - $12.98 | +1.08% | Beat | -11.0% | 23 | 3 up, 0 down | Apr 29, 2026 | $39.65B |
| Dec 31, 2025 | -$3.96 | -$3.99 | -$4.33 - -$3.45 | +0.75% | Beat | N/A | 24 | 0 up, 22 down | Feb 11, 2026 | $32.52B |
| Sep 30, 2025 | $3.24 | $2.91 | $0.66 - $3.35 | +11.34% | Beat | -22.1% | 25 | 0 up, 1 down | Nov 5, 2025 | $32.65B |
| Jun 30, 2025 | $6.27 | $5.87 | $4.50 - $8.28 | +6.81% | Beat | -9.9% | 23 | 3 up, 2 down | Jul 30, 2025 | $32.39B |
| Mar 31, 2025 | $11.58 | $10.07 | $8.53 - $10.92 | +14.99% | Beat | +60.2% | 23 | 2 up, 2 down | Apr 30, 2025 | $32.11B |
| Dec 31, 2024 | -$2.16 | -$2.12 | -$2.52 - -$1.10 | -1.89% | Miss | N/A | 23 | 2 up, 0 down | Feb 11, 2025 | $29.21B |
| Sep 30, 2024 | $4.16 | $3.39 | $2.68 - $3.90 | +22.71% | Beat | -46.5% | 22 | 1 up, 0 down | Oct 30, 2024 | $29.40B |
| Jun 30, 2024 | $6.96 | $5.86 | $4.96 - $6.74 | +18.77% | Beat | -22.1% | 21 | 0 up, 0 down | Jul 31, 2024 | $29.54B |
| Mar 31, 2024 | $7.23 | $6.00 | $5.76 - $8.11 | +20.50% | Beat | -22.9% | 19 | 1 up, 0 down | Apr 24, 2024 | $29.61B |
| Dec 31, 2023 | -$0.11 | $0.92 | -$0.12 - $2.15 | -111.96% | Miss | -106.8% | 11 | 0 up, 6 down | Jan 25, 2024 | $26.46B |
| Sep 30, 2023 | $7.78 | $7.17 | $7.05 - $7.53 | +8.51% | Beat | +13.1% | 19 | 1 up, 0 down | Nov 1, 2023 | $26.42B |
| Jun 30, 2023 | $8.94 | $8.83 | $8.14 - $9.20 | +1.25% | Beat | +3.1% | 21 | 1 up, 0 down | Aug 2, 2023 | $26.75B |
| Mar 31, 2023 | $9.38 | $9.20 | $8.98 - $9.46 | +1.96% | Beat | +16.7% | 19 | 1 up, 2 down | Apr 26, 2023 | $26.74B |
| Dec 31, 2022 | $1.62 | $1.46 | $1.35 - $1.66 | +10.96% | Beat | +30.6% | 20 | 0 up, 0 down | Feb 1, 2023 | $22.44B |
| Sep 30, 2022 | $6.88 | $6.28 | $6.15 - $6.53 | +9.55% | Beat | +42.4% | 18 | 3 up, 0 down | Nov 2, 2022 | $22.80B |
| Jun 30, 2022 | $8.67 | $7.67 | $7.36 - $8.05 | +13.04% | Beat | +25.8% | 21 | 0 up, 1 down | Jul 27, 2022 | $23.66B |
| Mar 31, 2022 | $8.04 | $6.80 | $6.44 - $7.20 | +18.24% | Beat | +4.8% | 20 | 2 up, 0 down | Apr 27, 2022 | $23.97B |
| Dec 31, 2021 | $1.24 | $1.16 | $1.06 - $1.77 | +6.90% | Beat | N/A | 21 | 0 up, 0 down | Feb 2, 2022 | $21.05B |
| Sep 30, 2021 | $4.83 | $4.67 | $4.28 - $5.12 | +3.43% | Beat | +56.8% | 19 | 0 up, 1 down | Nov 3, 2021 | $20.70B |
| Jun 30, 2021 | $6.89 | $6.84 | $6.02 - $7.86 | +0.73% | Beat | -45.1% | 21 | N/A | Jul 28, 2021 | $20.64B |
| Mar 31, 2021 | $7.67 | $7.10 | $6.65 - $8.63 | +8.03% | Beat | +42.0% | 19 | N/A | Apr 28, 2021 | $20.67B |
| Dec 31, 2020 | -$2.30 | -$2.32 | -$2.44 - -$2.24 | +0.86% | Beat | -200.9% | 19 | N/A | Feb 3, 2021 | $19.06B |
| Sep 30, 2020 | $3.08 | $2.80 | $2.50 - $3.21 | +10.00% | Beat | -38.8% | 23 | N/A | Nov 3, 2020 | $20.07B |
| Jun 30, 2020 | $12.56 | $10.12 | $9.55 - $11.74 | +24.11% | Beat | +107.6% | 22 | N/A | Aug 5, 2020 | $19.08B |
| Mar 31, 2020 | $5.40 | $4.69 | $4.46 - $5.73 | +15.14% | Beat | +20.5% | 20 | N/A | Apr 29, 2020 | $18.93B |
| Dec 31, 2019 | $2.28 | $2.19 | $2.14 - $2.24 | +4.11% | Beat | -14.0% | 23 | N/A | Feb 5, 2020 | $16.30B |
| Sep 30, 2019 | $5.03 | $4.57 | $4.42 - $4.82 | +10.07% | Beat | +9.8% | 23 | N/A | Nov 6, 2019 | $16.24B |
| Jun 30, 2019 | $6.05 | $5.27 | $4.49 - $5.47 | +14.80% | Beat | +52.8% | 21 | N/A | Jul 31, 2019 | $16.25B |
| Mar 31, 2019 | $4.48 | $4.30 | $4.14 - $4.48 | +4.19% | Beat | +33.3% | 21 | N/A | May 1, 2019 | $16.11B |
| Dec 31, 2018 | $2.65 | $2.53 | $2.49 - $2.57 | +4.74% | Beat | +28.6% | 21 | N/A | Feb 6, 2019 | $14.17B |
| Sep 30, 2018 | $4.58 | $4.24 | $3.81 - $4.42 | +8.02% | Beat | +35.1% | 20 | N/A | Nov 7, 2018 | $14.21B |
| Jun 30, 2018 | $3.96 | $3.78 | $3.70 - $3.87 | +4.76% | Beat | +13.5% | 19 | N/A | Aug 1, 2018 | $14.26B |
| Mar 31, 2018 | $3.36 | $3.20 | $3.08 - $3.25 | +5.00% | Beat | +22.2% | 17 | N/A | May 2, 2018 | $14.28B |
| Dec 31, 2017 | $2.06 | $2.00 | $1.95 - $2.12 | +3.00% | Beat | -1.4% | 20 | N/A | Feb 7, 2018 | $13.19B |
| Sep 30, 2017 | $3.39 | $3.27 | $3.10 - $3.42 | +3.67% | Beat | +6.6% | 14 | N/A | Nov 8, 2017 | $13.28B |
| Jun 30, 2017 | $3.49 | $3.06 | $2.85 - $3.30 | +14.05% | Beat | +51.7% | 18 | N/A | Aug 2, 2017 | $13.53B |
| Mar 31, 2017 | $2.75 | $2.63 | N/A | +4.56% | Beat | +47.8% | N/A | N/A | May 3, 2017 | $13.76B |
| Dec 31, 2016 | $2.09 | $2.06 | N/A | +1.46% | Beat | +44.1% | N/A | N/A | Feb 8, 2017 | $12.88B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $17.13, up 5.8% from the year before. It was $9.43 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $17.13 | +5.8% |
| Dec 31, 2024 | $16.19 | -37.7% |
| Dec 31, 2023 | $25.99 | +3.1% |
| Dec 31, 2022 | $25.21 | +22.2% |
| Dec 31, 2021 | $20.63 | +10.1% |
| Dec 31, 2020 | $18.74 | +5.0% |
| Dec 31, 2019 | $17.84 | +22.6% |
| Dec 31, 2018 | $14.55 | +24.5% |
| Dec 31, 2017 | $11.69 | +24.0% |
| Dec 31, 2016 | $9.43 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,600 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,559 | 15 | |
| 2026Q2 | Jun 30, 2026 | 7,573 | 17 | |
| 2026Q1 | Mar 31, 2026 | 8,273 | 19 | |
| 2025Q4 | Dec 31, 2025 | 9,159 | 21 | |
| 2025Q3 | Sep 30, 2025 | 7,477 | 21 | |
| 2025Q2 | Jun 30, 2025 | 6,781 | 19 | |
| 2025Q1 | Mar 31, 2025 | 6,602 | 20 | |
| 2024Q4 | Dec 31, 2024 | 7,882 | 18 |
2026Q3 Earnings Call
Opening remarks
Lisa Stoner Vice President of Investor Relations Thank you, and good morning. We will begin this morning with brief remarks from Jim Rechtin, Humana's President and Chief Executive Officer, and Chief Financial Officer Celeste Mellet. Following these remarks, we will host a question-and-answer session with industry analysts. Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our third quarter 2026 earnings press release as they relate to forward-looking statements, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results. Today's press release and posted remarks, our historical financial news releases, and our filings with the SEC are also available on our Investor Relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Any reference to earnings per share or EPS made during this conference call refers to diluted earnings per common share. Finally, this call is being recorded for replay purposes. That replay will be available on the Investor Relations page of Humana's website, humana.com, later today. With that, I'll turn it over to Jim.
James Rechtin President and Chief Executive Officer Thank you, Lisa. Good morning, everyone, and thank you for joining us. We have just one headline today, and that is that we are in a good place. Execution is strong and improving, signs point to our strategy working, and we are increasingly seeing the tangible results of our team's good work. The results are positive for our members, our patients, and their health, and the results are contributing to our margin and earnings growth recovery, which is moving from on plan toward being ahead of the plan. As usual, I will frame my comments today around the four drivers of our business: one, product and experience, which drive customer retention and growth; two, clinical excellence, which delivers clinical outcomes and medical margin; three, highly efficient operations; and four, capital allocation and growth in both CenterWell and Medicaid. Let's start with product and experience. Our 2026 membership, both new and returning, is performing in line with or better than expected. Our 2027 product positioning also appears to be in line with expectations.
Frequently Asked Questions About HUM
When is Humana's next earnings date?
Humana's next earnings report is expected for Feb 9, 2027.
Did HUM beat earnings estimates last quarter?
Yes. Humana reported EPS of -$0.70 for the quarter ended Sep 30, 2026, above the -$1.03 estimate, a 32.04% surprise.
What EPS do analysts expect from HUM next quarter?
The consensus EPS estimate for Humana for the quarter ending Dec 31, 2026 is -$7.60 from 27 analysts, with estimates from -$7.68 to -$6.94.
How often does HUM beat earnings estimates?
Humana beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +10.93%.
HUM pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors